REMINDER: Microbot Medical to Highlight FDA 510(k) Clearance of the LIBERTY Endovascular Robotic System at the H.C. Wainwright Annual Investor Conference

Core Insights - Microbot Medical Inc. has received FDA clearance for its LIBERTY Endovascular Robotic System, marking it as the first single-use, remotely operated robotic system for peripheral endovascular procedures [1][2]. Company Overview - Microbot Medical Inc. is a medical device company focused on transforming endovascular procedures through advanced robotic technology [2]. - The LIBERTY Endovascular Robotic System is designed for precision, efficiency, and provider safety, supported by a strong intellectual property portfolio [2]. Event Announcement - Harel Gadot, CEO, President & Chairman of Microbot Medical, will present at the H.C. Wainwright Annual Investor Conference, highlighting the recent FDA clearance of the LIBERTY System [1]. - The presentation is scheduled for September 9 at 9:00am ET and will be available via a live webcast on the company's website [1].